ReviewLasers in medical science2026
Photobiomodulation for salivary gland dysfunction: aligning clinical expectations with etiology-dependent treatment responsiveness.
Review in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To discuss how distinct pathogenic mechanisms underlying salivary gland dysfunction may influence responsiveness to photobiomodulation (PBM) in patients with hyposalivation and xerostomia. A narrative review was conducted focusing on the biological and clinical factors potentially associated with PBM responsiveness across different etiologies of salivary gland dysfunction, including Sjögren's disease, chemotherapy-induced dysfunction, radiation-induced salivary gland injury, and polypharmacy-associated hyposalivation. Mechanisms related to inflammation, oxidative stress, fibrosis, neurosecretory impairment, residual glandular viability, and persistence of etiological burden across different etiologies of salivary gland dysfunction were comparatively discussed. Therapeutic success assessments were also explored, emphasizing that symptom improvement and enhancement of oral quality of life may occur even in the absence of complete salivary flow normalization. In addition, the currently available evidence regarding PBM responsiveness in distinct etiological scenarios was critically presented, highlighting its heterogeneous and unbalanced distribution across conditions. Future directions involving biologically informed, individualized, and combination-based therapeutic approaches were also discussed. PBM responsiveness should not be interpreted as universally predictable across all etiologies of hyposalivation. Instead, therapeutic outcomes likely depend on several factors. Biologically informed and individualized approaches may contribute to more realistic therapeutic expectations and more personalized management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.